PortSight Med
Implantable Venous Access Device
Health Tech & Life Sciences
Non Active, May 2022 ceased to operate
Company Overview
Snapshot
Founded in January 2016 by Dean Nachman, PortSight Med operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. In May 2022, PortSight Med ceased operations.
Business overview
PortSight Med is developing an implantable venous access device designed with patented optical characteristics. This technology enables easy, noninvasive trans-illumination of the port through a patient's skin, aiming to simplify and enhance the reliability of port location and needle access. The company operates within the Health Tech & Life Sciences sector, focusing on medical devices, medical technologies, and vascular solutions for healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is PortSight Med's primary product?
- PortSight Med develops a novel, totally implantable venous access device featuring patented optical characteristics for easy, noninvasive trans-illumination through the patient's skin.
- When was PortSight Med founded?
- PortSight Med was founded in January 2016.
- Who is a co-founder of PortSight Med?
- Dean Nachman is a co-founder and CTO of PortSight Med.
- What is the operational status of PortSight Med?
- PortSight Med ceased operations in May 2022.